Overview

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

Status:
Active, not recruiting

Trial end date:
2022-01-14

Target enrollment:

Participant gender:

Summary

This study is to find out if administration of stereotactic radiosurgery (SRS) given after Nivolumab will improve overall response rate/anti-tumor activity in patients with metastatic breast cancer with brain metastases.

Phase:

Phase 1

Details

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Nivolumab